Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors? Daniel V. SantiGary W. AshleyFrancois-Clement Bidard Current Opinion Open access 18 January 2024 Pages: 171 - 176
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases Suxiang ChenSaumya Nishanga HeendeniyaRakesh N. Veedu Leading Article Open access 22 January 2024 Pages: 177 - 203
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies Chantal T. HarrisSivan Cohen Review Article Open access 23 January 2024 Pages: 205 - 226
Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases Luke M. TomasovicKathy LiuJamie B. Spangler Review Article 24 November 2023 Pages: 227 - 248
Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease Karen ManoutcharianGoar Gevorkian Review Article Open access 27 January 2024 Pages: 249 - 257
Nano–Bio Interactions: Exploring the Biological Behavior and the Fate of Lipid-Based Gene Delivery Systems Seigo KimuraHideyoshi Harashima Review Article 12 February 2024 Pages: 259 - 273
Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System Emanuela Elisa SorbaraMaria Antonietta BarbieriEdoardo Spina Original Research Article 25 February 2024 Pages: 275 - 285
Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study Ching-Liang HoTsu-Yi ChaoHsuan-Yu Lin Original Research Article 09 January 2024 Pages: 287 - 299
Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study Gyeongseon ShinByung Soo KimSeungJin Bae Original Research Article Open access 12 January 2024 Pages: 301 - 311
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers Xiaojiao LiBing LiYanhua Ding Original Research Article 27 December 2023 Pages: 313 - 321
Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries Hyunjung WooGyeongseon ShinSeungJin Bae Correction Open access 22 January 2024 Pages: 323 - 323
